Tonight at 7:30pm on #YaleCancerAnswers, Dr. Tracy Battaglia joins to discuss the impact of #insurance subsidies on #cancercare. 🎧Listen live #WNPR 🔁Download #ApplePodcasts 💻Listen later #YouTube

Dr. Veronica Chiang shares updates on three #clinicaltrials she is leading that target brain metastases. #brainmets medicine.yale.edu/news-article...

Thank you to Dr. Scott Lowe @mskcancercenter.bsky.social for presenting #GrandRounds on potential programs to reveal and exploit the strategies nature uses to combat #cancer, including the impact of #p53 in #tumorsuppression. Watch his full talk: youtube.com/watch?v=B6pj....

New research finds that even low levels of physical activity shift glucose away from tumors and toward working muscles, limiting cancer’s fuel supply. "Any amount of activity may be beneficial,” explains Dr. Rachel Perry. medicine.yale.edu/news-article...

How are we advancing care for cutaneous malignancies? Tune in to #SmilowShares on #YouTube to hear experts discuss management strategies and the evolving role of neoadjuvant therapy. ▶️ Watch: youtu.be/_nNJAgbxaIU?...

Today at 12pm, we are pleased to welcome Dr. Scott Lowe @mskcancercenter.bsky.social as our #GrandRounds lecturer, presenting "Targeting the intersection between senescence and cancer." Join us in Smilow Auditorium or online via Zoom: bit.ly/49lM8u1.

A Phase 1 study by Dr. Noffar Bar @yale-hematology.bsky.social shows subcutaneous alnuctamab #ALNUC is active in #RRMM, with a 58–71% response rate, ~50% of patients achieving MRD negativity, and better safety than IV dosing. #multiplemyeloma www.nature.com/articles/s41...

Dr. Jacquelyne Gaddy co-moderated a panel Q&A on #rectalcancer at #ASCOGI26. meetings.asco.org/meetings/2026-… @ascocancer.bsky.social

This morning at #ASCOGI26, Dr. Xuanyi Li presented research on ALK fusions in #colorectalcancer. meetings.asco.org/meetings/202... @ascocancer.bsky.social

Today starting at 11:30am PST/2:30pm EST, Dr. Christopher Rodman presents research on #pancreaticcancer. Stop by Poster Session B at #ASCOGI26! meetings.asco.org/meetings/202... @ascocancer.bsky.social

Research led by @muschenlab.bsky.social shows B-cell acute lymphoblastic leukemia may be vulnerable to drugs originally developed for Alzheimer’s & Parkinson’s diseases. The study finds GSK3B inhibitors can overcome drug resistance + help prevent relapse in B-ALL. medicine.yale.edu/cancer/news-...

Social media works! New research shows it can effectively test and disseminate messages and surveys that raise awareness about #ProstateCancer, #genetics + their connections to other cancers. cancer.jmir.org/2025/1/e69787 @jmirpub.bsky.social

Congratulations to Dr. Amin Nassar, named a recipient of an Emerging-Generation Award by @the-asci.org. E-Gen Awards recognize post-MD, pre–faculty appointment physician-scientists who are meaningfully engaged in immersive research.

Dr. Ammanuel Taye is presenting research on #gastriccancer today at #ASCOGI26. Stop by Poster Session A this morning starting at 11:30am PST. meetings.asco.org/meetings/202... @ascocancer.bsky.social

#ASCOGI26 begins today. Join @sundarraghav.bsky.social during Poster Session A starting at 11:30am PST/2:30pm EST. meetings.asco.org/meetings/202... @ascocancer.bsky.social

While nutrition + exercise was shown to improve QoL post-treatment for #breastcancer, a recent study led by Leah Puklin, MPH, found nutrition + exercise had no impact on treatment-related declines during chemotherapy. academic.oup.com/jncics/advan...

From risk to survivorship, explore key clinical considerations in #breastcancer care at our free networking and #CME dinner, Wed., Jan. 28 at 6pm in Westerly, RI. Presenters: Drs. Robert Legare, Anca Bulgaru, Mary Jane Minkin, Jill Banatoski + @maryamlustberg.bsky.social. ➡️RSVP: bit.ly/48QFOcc

@scottcapozza.bsky.social joins Dr. Eric Winer tonight on #YaleCancerAnswers to discuss the vital role #exercise plays in recovery from #cancer treatment. 🎧Listen live on #WNPR 🔂Download on #ApplePodcasts 💻Watch on #YouTube

De. Jensa Morris joins #YaleCancerAnswers tonight at 7:30pm to talk about the critical role #hospitalists play in #cancer care and helping patients recover faster + spend less time in the hospital. 🎧Listen live on #WNPR 🔁Download #ApplePodcasts 💻Watch on #YouTube

Dr. Roy Herbst commented on #TheLead with #JakeTapper: "When #lungcancer is found early, and we use all different modalities bringing surgery, radiation and all scientific advances together, the prognosis can be quite good." #BarryManilow @yaleschoolofmed.bsky.social

Join us Wednesday, Jan. 28 at 6pm for a free networking and #CME dinner on women's health + #breastcancer. Presenters include Drs. Robert Legare, Anca Bulgaru, Mary Jane Minkin, Jill Banatoski, and @maryamlustberg.bsky.social. ➡️RSVP bit.ly/48QFOcc

Tonight on #YaleCancerAnswers, Dr. Daniel O'Neil discusses the latest research on improving #breastcancer outcomes in low-middle income countries. 🔸Listen live on WNPR 🔸Download via Apple Podcasts 🔸Watch on YouTube

Dr. Roy Herbst stopped by the Yale Medical Oncology-Hematology Fellows' holiday dinner last night to deliver some holiday cheer!

The #WISDOM study looked at risk-based screening for #breastcancer + results were presented at #SABCS25. Dr. Eric Winer: "It is practice-changing, and I think it has huge public health implications.” ➡️ www.nytimes.com/2025/12/12/h...

Congratulations to Dr. Shilpa Murthy, recipient of a Defense Health Agency Career Development Award! medicine.yale.edu/news-article... @pamelakunzmd.bsky.social

Join us for #Pathology Grand Rounds on Thursday, Dec. 18 at 12:30 PM ET as W. Fraser Symmans, MBChB, of @mdanderson.bsky.social, presents on, “Prognosis & Prediction in Adjuvant Treatment of Hormone Receptor-Positive Breast Cancer’ @yaleschoolofmed.bsky.social @yalecancer.bsky.social bit.ly/4pDVhDG

Congratulations to @maryamlustberg.bsky.social, named by @oncodaily.bsky.social as one of the 100 Influential Women in Oncology to follow on social media in 2025! oncodaily.com/community/10...

Dr. Luisa Escobar-Hoyos was awarded the 2025 Dr. Ralph and Marian Falk Medical Research Trust Transformational Award which includes a $1M grant to support her team’s #pancreaticcancer research. medicine.yale.edu/news-article...

Dr. Patricia LoRusso joins #YaleCancerAnswers at 7:30pm to discuss #cancer breakthroughs that made headlines in 2025, and how new therapies move from #clinicaltrials ➡️ FDA approvals. 🎧Listen live on WNPR 🔁Download Apple Podcasts 💻Watch on YouTube @theaacr.bsky.social

Drs. Jessica Liu and Guannan Gong present new data #SABCS25 showing automated #ClinicalTrial Patient Matching (CTPM) helps identify diverse trial candidates, but additional strategies are needed to boost participation. @maryamlustberg.bsky.social

De. Adam Krysztofiak shares how HER2-targeted triplex-forming oligonucleotides (TFOs) cause DNA damage + trigger cell death in HER2+ #breastcancer cells. They turn on the immune system, offering a new way to improve responses + overcome resistance to HER2 therapies. #sabcs @oncoalert.bsky.social

Dr. Devora Isseroff shares how ctDNA monitoring in #breastcancer (TNBC & HR+) found pt anxiety remained stable in ctDNA-negative individuals. For ctDNA-positive results, physicians reported ⬇️confidence in treatment decisions, highlighting uncertainty. #SABCS25 @oncoalert.bsky.social

Drs. Jiawei Dai & Lajos Pusztai show TCGA/BEAUTY data #SABCS25, germline changes hit cell cycle/DNA repair/telomeres, somatic mutations affect adhesion/metabolism/signaling. Their CanSys tool visualizes these pathway disruptions per patient. @oncoalert.bsky.social

Ismail Ajjawi @yaleschoolofmed.bsky.social ’27 presents data on premenopausal women with early-stage HR+/HER2– node-negative #breastcancer at #SABCS25 • Chemo use ⬇️ 35%→24% • 72% omitted chemo, w/no difference in 5-yr OS @oncoalert.bsky.social @sabcs.bsky.social @maryamlustberg.bsky.social

At #SABCS25, Dr. Julian Lin and Dr. Lajos Pusztai report that #breastcancer genes with frequent copy number amplifications and membrane protein overexpression may represent new #ADC targets. @oncoalert.bsky.social @sabcs.bsky.social

@maryamlustberg.bsky.social presents #REPOWER at #SABCS25 —an intl study of pts with stage II/III HR+/HER2- early #breastcancer receiving adjuvant ribociclib + endocrine therapy. @oncoalert.bsky.social @sabcs.bsky.social

Dr. Eric Winer at #SABCS25 reframed how to think about #breastcancer subsets and reminded attendees that #DCIS treatment depends on clear patient education and patient-led decisions. “There is not simply a right choice.” @sabcs.bsky.social

The S2409 PRISM trial biomarker-tests patients with extensive stage small cell #LungCancer during induction treatment and assigns them to 1 of 3 maintenance therapy cohorts based on #SCLC subtype and SLFN11 status. #LCSM Co-PI: So Yeon Kim, MD Yale Cancer Center swog.org/clinical-trials/S2409

Dr. Jack Robbins shares new data from @yalepathology.bsky.social showing that HER2 measured by Troplex™ is linked to longer benefit from T-DXd, while higher TROP2 surprisingly predicts shorter response #SABCS25. @sabcs.bsky.social @oncoalert.bsky.social

Dr. Mariya Rozenblit highlights how C1D15 DiviTum® TKa levels can uncover early adherence issues or drug interactions during CDK4/6 inhibitor therapy. #SABCS25 Takeaway: DiviTum® TKa is a practical early biomarker to optimize breast cancer treatment outcomes. @sabcs.bsky.social

New research from Dr. Lajos Pusztai #SABCS25 shows RNA levels of ESR1, PGR closely match traditional estrogen receptor/progesterone receptor test results in #breastcancer. @foundationmedicine.bsky.social @sabcs.bsky.social @oncoalert.bsky.social

Dr. Guannan Gong shares how an #AI-driven patient-matching system improved ID of eligible patients for #breastcancer trials + increased representation of under-enrolled groups. #SABCS25 @maryamlustberg.bsky.social @sabcs.bsky.social @oncoalert.bsky.social

Dr. Tristan Jordan shows how invasive lobular carcinoma #ILC + invasive ductal carcinoma #IDC #breastcancer respond differently to neoadjuvant therapy: ILC shows poorer response in TNBC but similar outcomes in ER+/HER2– & HER2+ subtypes. #SABCS25 @yalepathology.bsky.social @oncoalert.bsky.social

@ncasasanta.bsky.social presents data at #SABCS25: In advanced #breastcancer, genomic profiling shows younger women more frequently have BRCA1/2, TP53, HRD, and PD-L1 alterations, while older women more often exhibit ESR1, PIK3CA, CDH1, and higher TMB. @sabcs.bsky.social @oncoalert.bsky.social

Powerful message from Dr. Amy Beumer at #SABCS25: It’s time to “fix the toxic friendship” and design dosing with patients—balancing side effects, quality of life, and longevity. @maryamlustberg.bsky.social @sabcs.bsky.social

@maryamlustberg.bsky.social highlights why patient-reported outcomes (PROs) must be central to oncology drug development and clinical trials at #SABCS25: "Partnering with our patients and patient advocacy organizations is the path forward." @sabcs.bsky.social

Dr. David Rimm @yalepathology.bsky.social moderates Translational Controversies: ADCs, Targeted Therapy, or Chemo? at #SABCS25, sharing how ADCs fit into #breastcancer treatment, + whether they act more like targeted therapies or chemotherapy with #pathology + #oncology perspectives.

@maryamlustberg.bsky.social breaks down key insights on hormone replacement therapy #HRT for #breastcancer survivors at #SABCS25: "We are not the hormone police—our role is to empower patients." @sabcs.bsky.social

Important conversation at #SABCS25 on hormone replacement therapy in breast cancer care with Drs. @lisalarkinmd.bsky.social, Jewel King, Thelma Brown, @maryamlustberg.bsky.social, and Tara Sanft. @theaacr.bsky.social @sabcs.bsky.social

@maryamlustberg.bsky.social highlights the major unmet needs in #menopause care after #breastcancer at #SABCS25. “Our patients have a lot of symptoms and they are not always being addressed — we need to do a lot better.” @sabcs.bsky.social